Novartis And Bayer To Go Head To Head Following EU Extavia Approval

Swiss drugmaker Novartis has obtained EU approval for its multiple sclerosis (MS) treatment Extavia (interferon beta-1b), which will result in a head-to-head battle with Bayer's identical competitor drug Betaferon. The drug is expected to be launched in the EU in the first half of

To read the full article, please choose one of the following options: